Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review

Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review

<b>Background/Objectives</b>: To conduct a systematic review to evaluate the detection rates (DR) of the three FDA-approved PSMA-targeted radiopharmaceuticals in patients with recurrent prostate cancer. <b>Methods</b>: Two individuals systematically searched MEDLINE, ScienceD...

Full description

Saved in:

Bibliographic Details
Main Authors:	Soroush Rais-Bahrami, Phillip Davis, Albert Chau, Samuel J. Galgano, Brian F. Chapin, David M. Schuster, Catriona M. Turnbull
Format:	Article
Language:	English
Published:	MDPI AG 2025-05-01
Series:	Diagnostics
Subjects:	biochemical recurrence prostate cancer imaging prostate specific membrane antigen positron emission tomography
Online Access:	https://www.mdpi.com/2075-4418/15/10/1224
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PSMA PET/CT for prostate cancer diagnosis: current applications and future directions
by: Zhengang Shen, et al.
Published: (2025-05-01)

The Performance and Role of PSMA PET Scans in Localised Prostate Cancer
by: Jianliang Liu, et al.
Published: (2025-02-01)

Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients
by: Aravintho Natarajan, et al.
Published: (2019-07-01)

The value of habitat analysis based on 18F-PSMA-1007 PET/CT images for prostate cancer risk grading
by: Yang Wang, et al.
Published: (2025-07-01)

68Ga-PSMA PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy
by: Yuigi Yuminaga, et al.
Published: (2021-04-01)

Indications and Results for Ga-68 PSMA PET/CT in Patients with Biochemical Relapse of Prostate Cancer
by: Ivan Rogić, et al.
Published: (2024-01-01)

Updates on controversies surrounding the staging and management of newly diagnosed localized prostate cancer using prostate-specific membrane antigen (PSMA) positron emission tomography
by: Patricia Tai, et al.
Published: (2025-07-01)

High Detection Rates for Prostate-specific Membrane Antigen–avid Prostate Cancer Recurrence at Low Prostate-specific Antigen levels on Extended Axial Field-of-view Positron Emission Tomography/Computed Tomography
by: Sarah Thomas, et al.
Published: (2025-01-01)

The potential of generative AI with prostate-specific membrane antigen (PSMA) PET/CT: challenges and future directions
by: Islam Md Zobaer, et al.
Published: (2025-01-01)

Characterizing PSMA heterogeneity in prostate cancer and identifying clinically actionable tumor associated antigens in PSMA negative cases
by: Yelin Mulati, et al.
Published: (2025-07-01)

Is Copper-61 the New Gallium-68? Automation and Preclinical Proof-of-Concept of <sup>61</sup>Cu-Based Radiopharmaceuticals for Prostate Cancer Imaging
by: Diana Rodrigues, et al.
Published: (2025-03-01)

Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer
by: Marcus Edward Asokendaran, et al.
Published: (2019-07-01)

Metastasis directed radiotherapy versus standard of care for PSMA-PET diagnosed oligometastatic/oligoprogressive castration resistant prostate cancer
by: Laura Bauersachs, et al.
Published: (2025-07-01)

[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine
by: Cato C. Loeff, et al.
Published: (2024-11-01)

A pilot study of PSMA-targeted F-18-DCFPyL PET imaging of patients with adenoid cystic carcinoma
by: Andrew F. Voter, et al.
Published: (2025-05-01)

Secondary Analysis of PSA and BCR-Free Survival in Asian Prostate Cancer Patients
by: Gao X, et al.
Published: (2025-06-01)

PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer
by: Nicole Handa, et al.
Published: (2025-05-01)

PSMA-PET-derived distance features as biomarkers for predicting outcomes in primary prostate cancer post-radical prostatectomy
by: Ruohua Chen, et al.
Published: (2025-07-01)

A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer
by: Matthew J. Roberts, et al.
Published: (2025-07-01)

Testing the diagnostic accuracy of a 68Ga-PSMA PET Scan in Early Biochemical Recurrence of Prostate Cancer
by: Vigna-Taglianti Riccardo, et al.
Published: (2024-10-01)

Which PSMA PET/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study
by: Le Ma, et al.
Published: (2025-01-01)

PSMA response evaluation in follow-up PSMA-PET/CT after stereotactic ablative body radiotherapy (SABR) for oligometastases in prostate cancer
by: Anna-Lena Zang, et al.
Published: (2025-09-01)

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

Prostate-specific antigen and prostate-specific antigen kinetics in predicting 18F-sodium fluoride positron emission tomography-computed tomography positivity forfirst bone metastases in patients with biochemical recurrence after radical prostatectomy
by: James Yoon, et al.
Published: (2017-07-01)

Comparison of 18F-FDG and 68-PSMA-11 in PET for prostate cancer diagnosis
by: Natalia Fulle, et al.
Published: (2022-12-01)

Usefulness of prostate specific antigen density in detecting prostate carcinoma: A hospital-based study in patients with prostate biopsies
by: Reshmi Shrestha, et al.
Published: (2022-03-01)

Preclinical Evaluation of a Novel PSMA-Targeted Agent <sup>68</sup>Ga-NOTA-GC-PSMA for Prostate Cancer Imaging
by: Wenjin Li, et al.
Published: (2025-03-01)

The tumour sink effect on 68Ga-PSMA-PET/CT in metastatic castration-resistant prostate cancer and its implications for PSMA-RPT: a sub-analysis of the 3TMPO study
by: Atefeh Zamanian, et al.
Published: (2025-07-01)

The value of post radiotherapy prostate specific antigen dynamics for prostate cancer risk stratification models
by: Jane Shortall, et al.
Published: (2025-04-01)

An overview on prostate-specific membrane antigen uptake in malignancies other than prostate cancer: A pictorial essay
by: Esmail Jafari, et al.
Published: (2020-07-01)

Cinematic rendering of 18F‐DCFPyL PET/CT fusion data in a patient with metastatic clear cell renal cell carcinoma
by: Steven P. Rowe, et al.
Published: (2024-06-01)

The accuracy of ultrasensitive PSA in predicting disease progression after radical prostatectomy
by: Heikki Seikkula, et al.
Published: (2024-11-01)

Case report: Malignant priapism: penile metastasis from prostate cancer with low serum PSA level
by: Zhiqiang Zhang, et al.
Published: (2025-01-01)

68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for prostate cancer imaging: A narrative literature review
by: Jose Oliveira, et al.
Published: (2017-01-01)

Incidence of prostate adenocarcinoma in transurethral resection of the prostate patients
by: Yahia Ghazwani, et al.
Published: (2025-01-01)

Do fasting or high caloric drinks affect the physiological uptake of fluorine-18 prostate-specific membrane antigen-1007 in liver and bowel?
by: Kambiz Rahbar, et al.
Published: (2020-07-01)

Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer
by: Himisha Beltran, et al.
Published: (2025-08-01)

Clinicoradiological profile and treatment outcomes in prostate cancer at a tertiary care cancer center in India
by: Astha Rajput, et al.
Published: (2020-01-01)

Quality control and GMP synthesis of 68Ga-prostate-specific membrane antigen-11 for detection of low- and high-grade prostate cancer
by: Majid Assadi, et al.
Published: (2020-04-01)

Benign prostatic hyperplasia and prostate-specific antigen
by: Pejčić Tomislav, et al.
Published: (2015-01-01)